SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Avis Budget Group, Inc. engages in the provision of vehicle sharing and rental services. It operates through the Americas and International segments. The Americas segment includes vehicle rental and car sharing operations in North America, South America, Central America, and the Caribbean. The International segment is involved in vehicle rental and car sharing operations in Europe, the Middle East, Africa, Asia, and Australasia. The company was founded in 1946 and is headquartered in Parsippany, NJ.

Avis Budget Group Inc

Avis Budget Group (CAR) is currently gripped by an extreme short squeeze, with community discussion centered on its highly constrained float and reports that a small group of institutional holders control a majority of the shares. While many traders are enjoying significant gains from the stock's parabolic ascent, others are cautioning that the rampant volatility, frequent trading halts, and the potential for a share offering or institutional profit-taking make this a high-stakes, dangerous game of musical chairs.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is trending due to significant institutional interest and anticipation surrounding its role in the unfolding AI infrastructure supercycle, as investors weigh its potential to compete with major semiconductor peers. The community is actively debating the stock's recent price appreciation, with bulls pointing to strong CPU and GPU demand, while others caution against overstretched valuations following a prolonged period of positive momentum.

Velo3D, Inc. operates as a technology company, which engages in developing and manufacturing metal laser sintering printing machines for 3D printing. Its products include assure system, flow software, sapphire printer & sapphire XC. The company was founded by Benyamin Buller in June 2014 and is headquartered in Fremont, CA.

Velo3D Inc

Velo3D is surging on heavy volume as investors react to a significant multi-year contract with the Department of War and growing anticipation around the company's deepening ties to key aerospace and defense players. The community is actively debating the stock's massive short interest and potential for a squeeze against concerns over future capital raises and dilution, while bulls highlight the critical nature of its additive manufacturing technology for mission-ready defense production.

American Airlines Group, Inc. is a holding company, which engages in the operation of a network carrier through its principal wholly owned mainline operating subsidiary, American. The firm offers air transportation for passengers and cargo. It operates through the following geographical segments: Domestic, Latin America, Atlantic, and Pacific. The company was founded on December 9, 2013, and is headquartered in Fort Worth, TX.

American Airlines Group Inc

American Airlines is trending as investors grapple with the airline's significant debt load, rising jet fuel costs, and recent volatility sparked by merger rumors and regional geopolitical instability. The community is actively debating the stock's long-term viability, with many closely tracking updates on potential conflict-related supply disruptions and the company's ability to manage fuel-intensive operations.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

BioCryst Pharmaceuticals is currently a focal point for investors due to intensifying acquisition speculation and consistent institutional buying patterns, which have created a tightly compressed trading range. While the community debates the validity of buyout rumors and critiques the company's long-term performance, high levels of dark pool activity and heavy option volume suggest sophisticated market participants are positioning for a potential catalyst.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bear 3X ETF

Direxion Daily Semiconductor Bear 3X Shares

Investors are actively debating whether the semiconductor sector is currently in a parabolic bubble or if the relentless streak of green days is a temporary distortion, leading to significant frustration among those shorting the stock. Community sentiment is deeply polarized as traders weigh the impact of geopolitical headlines, upcoming earnings reports, and the aggressive upward momentum of the sector.

FuelCell Energy, Inc. engages in the business of developing, designing, producing, constructing, and servicing high temperature fuel cells for clean electric power generation. It operates through the following geographical segments: the United States, South Korea, and Europe. The company was founded by Bernard Baker and Martin G. Klein in 1969 and is headquartered in Danbury, CT.

Fuelcell Energy Inc

FuelCell Energy is seeing significant volatility driven by intense community debate over a potential short squeeze, with investors closely watching for a major data center contract to validate the firm's pivot toward AI infrastructure. While bulls emphasize technical breakout patterns and growing pipeline opportunities, bears remain vocal about persistent share dilution and the absence of definitive new deals.

T-Mobile US, Inc. engages in the provision of wireless communications services under the T-Mobile and MetroPCS brands. It offers postpaid and prepaid wireless voice, messaging and data services, and wholesale wireless services. The company was founded in 1994 and is headquartered in Bellevue, WA.

T-Mobile US Inc

T-Mobile is trending following a strong quarterly performance where it exceeded earnings estimates and raised its forward guidance, though the stock has faced localized selling pressure. The community is actively debating the company's competitive momentum against Verizon and AT&T, while investors are closely analyzing recent institutional activity and technical support levels.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is seeing a significant surge in momentum driven by aggressive institutional accumulation and positive commentary from the CFO regarding production orders and hyperscaler integration. The community is actively dismissing recent short-seller reports, focusing instead on the company's role as a key supplier in the high-growth AI optical interconnect market.

Abbott Laboratories engages in the discovery, development, manufacture, and sale of healthcare products. It operates through the following segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment refers to the line of branded generic pharmaceuticals manufactured worldwide and marketed and sold outside the United States in emerging markets. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, clinics, physicians' offices, retailers, government agencies, and alternate care testing sites. The Nutritional Products segment caters to the worldwide sales of pediatric and adult nutritional products. The Medical Devices segment includes a broad line of rhythm management, electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care and continuous glucose monitoring products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.

Abbott Laboratories

Abbott Laboratories is experiencing significant market attention following its earnings report and the strategic $23 billion acquisition of Exact Sciences. While the company faces pressure from adjusted growth guidance and ongoing litigation concerns, investors remain focused on long-term value, with many discussing the stock's potential for a re-rating as they navigate the integration of its expanded diagnostics footprint.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Altimmune Shareholders Approve All AGM Proposals, Boost Authorized Shares to 400M

Altimmune (NASDAQ:ALT) shareholders approved all proposals presented at the company's virtual annual meeting on April 16, 2026, including the election of nine directors and amendments that expand the...

Altimmune, Inc. (NASDAQ:ALT) Receives Consensus Rating of "Moderate Buy" from Brokerages

Altimmune, Inc. (NASDAQ:ALT - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the ten analysts that are covering the firm, Marketbeat Ratings reports. Two investment...

<ul class="summary-bullets"><li>The average 12-month price target on the stock is $18, representing a potential upside of as much as 495% from the stock’s current $3.02 trading levels.</li><li>The company is currently looking forward to initiating a late-stage trial of pemvidutide in MASH in 2026.</li><li>Truist believes that pemvidutide "could be successful in treating MASH as well as liver-related diseases AUD."</li></ul>Shares of Altimmune (ALT) traded 5% lower on Friday despite Wall Street viewing a potential upside of as much as 495% on the stock.According to data from Koyfin, nine of the 11 analysts covering the stock rate it ‘Buy’ or higher while one rates it ‘Hold’ and one has a ‘Sell’ rating on the shares.The average 12-month price target on the stock is $18, compared to the stock’s current $3.02 trading levels.<h2 class="st-heading-2">Wall Street Take</h2>Earlier this month, Truist initiated coverage of Altimmune with a ‘Buy’ rating and $12 price target. The firm believes that the company's lead candidate pemvidutide "could be successful in treating MASH."Truist is modelling peak 20,000 patients on pemvidutide, which would result in worldwide "peak adjusted/unadjusted revenue of ~$600million/$1.0billion," it said.<h2 class="st-heading-2">Altimmune Pipeline</h2>Altimmune is a clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases, including metabolic dysfunction-associated steatohepatitis (MASH). The company’s pemvidutide is in development for the treatment of alcohol use disorder (AUD) and alcohol-associated liver disease (ALD) in addition to MASH.The company is currently looking forward to initiating a late-stage trial of pemvidutide in MASH in 2026. The trial is expected to evaluate multiple pemvidutide doses over a 52-week treatment period.The company is looking forward to announcing topline data from a mid–stage trial of pemvidutide in Alcohol Use Disorder in the third quarter of 2026, and is also enrolling patients into a mid-stage trial of the drug in Alcohol-associated Liver Disease.<h2 class="st-heading-2">Retail Sentiment</h2>On Stocktwits, retail sentiment around ALT stock jumped from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume remained at ‘low’ levels.A Stocktwits user expressed disappointment about the stock’s downward trajectory.<stembedurl>https://www.stocktwits.com/Moemazon/message/648788986</stembedurl><a href="https://stocktwits.com/symbol/ALT">ALT stock</a> has dropped 45% over the past 12 months.Read More: <a href="https://stocktwits.com/news-articles/markets/equity/rckt-stock-dives-despite-gene-therapy-approval-wall-street-dismisses-sell-off/cZ3HfqIRImh">RCKT Stock Dives Despite Gene Therapy Approval — Wall Street Dismisses Sell-Off</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Altimmune logo is seen displayed on the screen of the tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

ALT Stock Has Nearly Halved In The Past Year, So Why Does Wall Street See Almost 500% Upside?

According to data from Koyfin, nine of the 11 analysts covering the stock rate it ‘Buy’ or higher while one rates it ‘Hold’ and one has a ‘Sell’ rating on the shares.

Equity

According to data from Koyfin, nine of the 11 analysts covering the stock rate it ‘Buy’ or higher while one rates it ‘Hold’ and one has a ‘Sell’ rating on the shares.


ALT Stock and the 2026 MASH Race: Dual Agonists vs. New Mechanisms

Altimmune heads into a pivotal 2026 MASH race, betting its dual agonist pemvidutide can stand out in a crowded field as key catalysts and risks converge.

Altimmune Stock: Neutral Outlook With Big 2026 Catalysts

Altimmune heads into 2026 with high-stakes catalysts as pemvidutide drives its pipeline, but funding needs and dilution risk loom alongside key clinical readouts.

ALT Pemvidutide Explained: What Makes It Different in MASH

Altimmune's pemvidutide targets MASH with dual glucagon/GLP-1 biology, showing mid-stage promise as it advances toward a high-stakes phase III study.

Anti-Aging Protein Research Takes a Step Forward with Cell Cloning

Anti-Aging Protein Research Takes a Step Forward with Cell Cloning Anti-Aging Protein Research Takes a Step Forward with Cell Cloning PR Newswire VANCOUVER, BC, March 24, 2026 Issued on behalf of Ava...

Altimmune (NASDAQ:ALT) Now Covered by Analysts at Truist Financial

Truist Financial initiated coverage on shares of Altimmune in a research note on Wednesday. They issued a "buy" rating and a $12.00 price target on the stock...

What is HC Wainwright's Estimate for Altimmune Q1 Earnings?

Altimmune, Inc. (NASDAQ:ALT - Free Report) - Equities researchers at HC Wainwright raised their Q1 2026 earnings estimates for Altimmune in a report released on Monday, March 16th. HC Wainwright...

HC Wainwright Forecasts Altimmune's Q4 Earnings (NASDAQ:ALT)

Altimmune, Inc. (NASDAQ:ALT - Free Report) - Analysts at HC Wainwright issued their Q4 2027 earnings per share (EPS) estimates for Altimmune in a report issued on Monday, March 16th. HC Wainwright...

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

Current Price	$3.43
Prev Close	$3.56
Open	$3.54
Dividend Yield	0.00%
50-Day Moving Average	$3.79
Beta	1.53
Avg. Volume	3.85M
PE Ratio	-3.51

52-Week High	$7.73
52-Week Low	$2.87
Market Capitalization	$463.05M
EPS (Annual)	-$0.9999
Price to Book	1.76
Revenue Per Employee	$719.30

ALT
Altimmune Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ALT News

ALTAltimmune Inc